Press release BoxID: 658953 (Nobel Biocare Deutschland GmbH)
  • Nobel Biocare Deutschland GmbH
  • Stolberger Straße 200
  • 50933 Köln
  • Contact person
  • Süha Demokan
  • +46 (31) 7788712

Nobel Biocare full year 2013 revenue up 2.2% (CER) with improving underlying profitability

(PresseBox) (Köln, ) .

Revenue for the full year at CER grew 2.2% versus prior year to EUR 566.8 million (-2.4% in EUR), representing the first annual growth at CER since 2007
Implants System representing 85% of Group revenue grew 3.3% (CER), outpacing estimated growth of market
Adverse currency impact on revenue -4.6pp, gross margin -0.4pp, EBIT margin -1.3pp
Operating profit (EBIT) of EUR 64.0 million reflecting a margin of 11.3%; excluding realignment costs and currency impacts EBIT margin at 13.4% (2012: 11.9%), owing to cost-saving initiatives yielding results
Net profit EUR 42.6 million (2012: EUR 46.1 million), proposed dividend unchanged at CHF 0.20

Richard Laube, CEO: "The 2013 results give us confidence that our strategy is working and that we have significantly strengthened the competitiveness of the business. Overall market conditions were far from ideal, but in this environment we achieved revenue growth at CER, for the first time since 2007, and we outgrew our peers. In 2013, we have further upped our investments in R&D, by over 10% and still improved the underlying EBIT margin. Our pipeline is rolling out, and our commercial partnering activities, and training and education are increasingly in place. This has led to an acceleration of growth in our high-margin core business, Implant Systems, the key indicator for the success of our strategy. The efficiency initiatives are progressing well and we are well positioned to continue gaining market share and improve profitability sustainably."